Table of Contents
Use this report to:
Learn about liver disease drug markets by various types and applications.
Receive information regarding different liver disease drugs in response to an increasing need for new and innovative drug treatments.
Analyze the regulatory environment, technologies, and market projections for liver treatment.
Learn about the application issues, including the latest trends and developments, in each liver disease drug category.
The global liver disease therapeutics market totaled nearly $24.5 billion in 2014 and is projected to approach $33.8 billion by 2019, registering a compound annual growth rate
(CAGR) of 6.7% through 2019.
The U.S. as a segment totaled nearly $9.1 billion in 2014 and should total $11.9 billion by 2019, with a CAGR of 5.6% for the period 2014-2019.
Rest of the world as a segment reached nearly $7.7 billion in 2014 and should reach $11.4 billion by 2019, with a CAGR of 8.1% between 2014 and 2019.
CAGR of 8.1% between 2014 and 2019.
BCC Research’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for liver disease drugs. The key
objective is to present a comprehensive analysis of the current liver disease drug market and its future direction by utilizing new methods for preventing globally
This report explores present and future strategies within the liver disease drug market, including market sizes, market leaders, market overview, and various other market
factors. The current state of the market, its setbacks, its innovations, and its future needs are also discussed.
A detailed analysis of the liver disease drug market and the industry structure has been conducted. This includes the different categories of liver disease drugs and the
various types of liver disease broken down by market share belonging to leading manufacturers and/or suppliers. Revenues for each disease type are broken down by
region. Sales figures are estimated for the five-year period from 2014 through 2019.
The strategies and the prospects of the current market are also discussed. Companies that manufacture and sell new and innovative liver disease-related drugs are also
REASON FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding different liver disease drugs in response to an increasing need for new and innovative drug
treatments. This industry is experiencing growth, as new product lines have been launched (e.g., Protease inhibitors for the treatment of hepatitis). The study looks at
most of the different drug types and different liver diseases, and cites the research and development for almost all new drugs and applications. The changes in market
behavior demonstrate the need to focus on this segment. Additionally, the study discusses the treatment options provided by these drugs to end-users.
This study examines the areas of growth in the liver disease drug market from the point of view of both manufacturers and users. This study will be of interest largely to
the pharmaceutical and biopharmaceutical industries, clinics, hospitals, and research institutes.
SCOPE OF THE STUDY
The scope of this study encompasses liver disease drug markets by various types. BCC Research analyzes each market by category with its applications in different regions of
the world. It also analyzes the regulatory environment, technology and market projections. Application issues include the latest trends and developments in each liver
disease drug category.
Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical
newsletters and journals, as well as many other sources. Projections were based on estimates such as the current number of end-users, potential end-users, mergers and
acquisitions and market trends.
Many companies within the industry were surveyed to obtain market data, including manufacturers, end-users of drug delivery systems, members of the pharmaceutical
and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC Research spoke with officials within the industry and also
consulted newsletters, company literature, product literature, technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key
terminology were completed. In addition, data were compiled from current financial, trade and government sources.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...
The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group ...